Amyndas Pharmaceuticals
@Amyndas
Followers
143
Following
25
Media
0
Statuses
38
#Amyndas is a pharmaceutical company developing #complement #therapeutics (#compstatins etc) for inflammatory diseases and disorders.
Joined December 2017
Excited to announce that @Amyndas is a partner of the #HorizonEurope-funded project @fibrotarget which aims to advance our understanding of #IBD #fibrosis & #fibrostenosis and explore new targets for disease diagnosis and therapy
🎉We're proud to announce that @fibrotarget is now in action🎉 This #HorizonEurope project aims to advance inflammatory bowel disease (#IBD) diagnosis and therapies🔬 You can learn more about the 5-year initiative below in our LIVE website🌐 https://t.co/yG6hNdHfXo
#fibrosis
0
0
1
We are thrilled to announce positive Phase 2 results for AMY-101 in adults with periodontal inflammation and gingivitis. Our study met both its primary and secondary endpoints with prominent resolution of periodontal inflammation.
amyndas.com
Amyndas announces positive top-line Phase 2 results for investigational AMY-101 in adults with periodontal inflammation and gingivitis Study met primary endpoint and key secondary endpoints with...
1
3
11
Massive congrats to @LambrisJD for making it to the #HighlyCited2020 researchers list of @webofscience for the third time in a row! A true pioneer in #complementbiology & #therapeutics, a #science mover and a #dogma shaker! Here's to many more! 👏👏 https://t.co/96SQ513cpD
clarivate.com
The Highly Cited Researchers 2025 list identifies and celebrates individuals who have demonstrated significant and broad influence in their fields of research. Through rigorous selection criteria and...
0
2
14
To #AMY101 θα δοκιμαστεί σε COVID-19 ασθενείς σε 6 νοσοκομεία της Ελλάδος
tovima.gr
Για πρώτη φορά ένα φάρμακο «made in Greece» θα χορηγηθεί σε ασθενείς νοσηλευόμενους με σύνδρομο οξείας αναπνευστικής δυσχέρειας εξαιτίας λοίμωξης με τον SARS-CoV-2 σε έξι ελληνικά νοσοκομεία
0
7
9
Delighted to report that our study comparing C3 & C5 inhibition in severe #COVID19 is now out! Promising results for #AMY101 Great team effort by @PennMedicine @SanRaffaeleMI @NCSR_Demokritos @infrathrace @Columbia @uni_ulm @UninaIT @usponline @Amyndas
https://t.co/oWcN9yhESm
4
29
54
Check out our new EXCITING data on the efficacy of AMY-101 in #COVID19 patients supporting the GREAT potential of #complement #C3 inhibition for a broad therapeutic effect. #AMY101 #thromboinflammation
Check out our new study comparing C3 inhibition with C5 blockade in #COVID19: our early clinical findings offer important insight into the differential mechanistic basis of C3 & C5 inhibition and support a broader therapeutic profile of #AMY101 in COVID-19 #thromboinflammation
0
3
7
Great achievement for our technology!
Complement fuels #COVID19 immunothrombosis and #C3 inhibition intercepts the #platelet #neutrophil NET-thrombin axis attenuating #NET-driven TF-induced thrombogenicity #AMY101 @Amyndas #therapy @PennMedicine @Aristoteleio @uoaofficial @NCSR_Demokritos #UniversityofThrace
0
3
7
Ευχαριστούμε τη Θεοδώρα Τσώλη και το @tovimagr για την συνέντευξη και εμπεριστατωμένη παρουσίαση του κλινικού προγράμματος αξιολόγησης της θεραπευτικής δράσης του αναστολέα C3 #ΑΜΥ101 σε ασθενείς #COVID19
tovima.gr
Μετά τα πρώτα θεαματικά αποτελέσματα, το σκεύασμα, το οποίο αναστέλλει την υπεραντίδραση του ανοσοποιητικού συστήματος, πήρε έγκριση για ταχεία και ευρεία κλινική δοκιμή
0
2
4
Complement C3 as a Target of Host Modulation in #Periodontitis: Following validation in NHP models of periodontal #inflammation, C3 inhibition moves to the bedside #complementbiology #oralcavity #dysbiosis #therapeutics #compstatins #AMY101
link.springer.com
Although originally identified as a blood-based antimicrobial system, complement is now regarded as a central regulator of immune and inflammatory responses and tissue homeostasis. When dysregulated...
1
2
5
Κορωνοϊός -Εγκριση από τον Αμερικανικό Οργανισμό Φαρμάκων στην ελληνική «Αμύντας» για κλινική δοκιμή σε ασθενείς
iefimerida.gr
Έγκριση από τον Αμερικανικό Οργανισμό Φαρμάκων (FDA) στην ελληνική φαρμακευτική «Αμύντας» για κλινική δοκιμή σε ασθενείς με κορωνοϊό.
0
1
1
We are thrilled to announce that the most advanced complement C3 inhibitor #AMY101 has received FDA approval for a randomized Phase 2 trial in #COVID19 patients with ARDS. AMY-101 suppresses cytokine release and thromboinflammation in COVID-19.
amyndas.com
Amyndas' Complement C3 Inhibitor AMY-101 receives FDA approval for a Phase 2 clinical trial in COVID-19 patients with ARDS
1
9
24
Κορωνοϊός: Ενθαρρυντικά τα αποτελέσματα φαρμάκου από την εταιρεία «Αμύντας»
iefimerida.gr
Η ελληνική φαρμακευτική εταιρεία «Aμύντας», σε συνεργασία με ένα διεθνές δίκτυο ερευνητών και κλινικών συνεργατών, δημοσίευσε σήμερα τα πρώτα κλινικά αποτελέσματα από την χορήγηση του πειραματικού...
0
3
3
Κορωνοϊός: Ενθαρρυντικά τα αποτελέσματα φαρμάκου από την εταιρεία «Αμύντας»
iefimerida.gr
Η ελληνική φαρμακευτική εταιρεία «Aμύντας», σε συνεργασία με ένα διεθνές δίκτυο ερευνητών και κλινικών συνεργατών, δημοσίευσε σήμερα τα πρώτα κλινικά αποτελέσματα από την χορήγηση του πειραματικού...
0
3
3
Excited to announce the first case of #COVID19 successfully treated with our #complement C3 therapeutic #AMY101 . Encouraging results open the window for therapeutic C3 inhibition by AMY101 in COVID19
0
5
12
Prospects have never been better for testing novel C3-targeted therapeutics in ocular indications #AMD Check out this new paper by our founder @LambrisLab reporting on the promising ocular PK profile of a fourth-generation #compstatin analog clinically developed by @Amyndas
Happy to share our recent paper on the promising #ocular PK and tissue distribution profile of a fourth-generation #compstatin-based #C3 inhibitor This work could lead to more effective ocular #therapeutics for diseases fueled by C3 dysregulation @Penn @Amyndas
0
1
2
Therapeutic targeting of the complement system - a new poster published today https://t.co/u5S0swWI9Z And for more, here's a recent review https://t.co/cxAOZGtTey
0
23
46
We’re thrilled that our Founder @Penn Prof John Lambris is on the #WebofScience #HighlyCitedResearchers 2019 list for the 2nd consecutive year! We’re grateful for his contributions in helping us develop the most advanced #ComplementTherapeutics #amyndas @ComplementSoc @LambrisLab
Congratulations to @Penn Prof John Lambris @LambrisLab for being recognized as a #WebofScience Highly Cited Researcher for a second consecutive year! We are all so very proud of you! #HighlyCited2019 @PennMedNews @webofscience @clarivate @ComplementSoc @AegeanConf
1
1
6
Academic research & industrial innovation are inherently connected. However, #stealth corporate research conducted outside the #peer_review system creates impediments to therapeutic #drug development. Read our comment now published in @NatImmunol Thread 1/
1
6
17
Our September issue is out! Read about targeting immunometabolism, complement therapeutics, oncolytic virotherapy, harnessing machine learning for cellular imaging and more https://t.co/dHxeSuKdbB
0
4
14